AstraZeneca reveals results of Phase III vaccine trial 100% protection against COVID-19 infection

The Lancet Medical Journal Preliminary analysis reports on Phase III clinical trials from research groups in the UK, Brazil and South Africa. Confirmation of the COVID-19 vaccine Of AstraZeneca (AstraZeneca) safe and effective in preventing COVID-19.

byNot found patients with symptoms.And must be admittedStudy in hospital after 22 The day after receiving the first vaccine Analysis results indicated after receiving the first dose. The vaccine showed an average effectiveness of 76%, with the vaccine being as effective as 82% when the interval between the first and second dose was 12 weeks or more.

Analysis of Phase III Clinical Trials by the University of Oxford and AstraZeneca. Showed that after receiving the first dose of vaccine The infection detection rate decreased 67% and after two doses of the vaccine. The infection detection rate dropped to 50% among 17,177 volunteers.

Sermene Pangalos, Executive Vice President, Biopharmaceutical Research and Development Said: “Preliminary analysis confirms that the vaccine against COVID-19 AstraZeneca’s products are effective in preventing severe infections and reducing the rate of hospitalizations. In addition, extending the time between first and second vaccination not only improves vaccine effectiveness. But it also increases the possibility of other people being vaccinated. The latest analysis also indicates that vaccines can reduce transmission. We therefore believe this vaccine will be effective in blocking the spread of COVID-19. Truly “

AstraZeneca also works with the government. International organizations and agencies around the world by the Thai government have approved the budget. 6,049,723,117 baht for the order of 26 million doses of the Covid 19 vaccine from AstraZeneca Company Limited.

The vaccine against COVID-19 AstraZeneca products can be stored and shipped at pre-existing conventional refrigeration equipment in the public health system (2 – 8 ° C) for at least 6 months. Existing medical packaging.